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Obestatin stimulates glucose-
induced insulin secretion through 
ghrelin receptor GHS-R
Geetali Pradhan1,2, Chia-Shan Wu1,3, Jong Han Lee1,4, Preeti Kanikarla1, Shaodong Guo3, Vijay 
K. Yechoor5, Susan L. Samson5 & Yuxiang Sun1,3
Orexigenic hormone ghrelin and anorexic hormone obestatin are encoded by the same preproghrelin 
gene. While it is known that ghrelin inhibits glucose-stimulated insulin secretion (GSIS), the effect of 
obestatin on GSIS is unclear. Ghrelin’s effect is mediated by its receptor Growth Hormone Secretagogue 
Receptor (GHS-R), but the physiologically relevant receptor of obestatin remains debatable. Here 
we have investigated the effect of obestatin on GSIS in vitro, in vivo and ex vivo, and tested whether 
obestatin regulates insulin secretion through GHS-R. We found that under hyperglycemic condition, 
obestatin augments GSIS in rat insulinoma cells (INS-1) and in pancreatic islets from ghrelin−/− mice. 
Surprisingly, obestatin-induced GSIS was absent in β-cells in which GHS-R was suppressed. Obestatin-
induced insulin secretion was abolished in the circulation of Ghsr−/− mice, and in pancreatic islets 
isolated from Ghsr−/− mice. We also found that obestatin-induced GSIS was attenuated in islets isolated 
from β-cell-specific Ghsr knockout MIP-Cre/ERT;Ghsrf/f mice. Our data collectively demonstrate that 
obestatin is a potent insulin secretagogue under hyperglycemic condition, and obestatin’s effect on 
insulin secretion is mediated by GHS-R in pancreatic β-cells. Our findings reveal an intriguing insight 
that obestatin and ghrelin have opposing effects on insulin secretion, and both are mediated through 
ghrelin receptor GHS-R.
Type 2 diabetes mellitus (T2DM) is a complex multifactorial disease that is characterized by insulin resistance, 
loss of pancreatic β-cell mass, and diminished β-cell function. Impairment of β-cell glucose-stimulated insulin 
secretion (GSIS) is a hallmark of type 2 diabetes. Understanding the regulation of insulin secretion in β-cells is 
essential for developing therapies for T2DM. Obestatin is a 23-amino-acid anorexic hormone that has been found 
to exert favorable effects on glucose homeostasis by increasing β cell mass, and by reducing systemic insulin 
resistance and adipose tissue inflammation1–5. These beneficial effects of obestatin make it an attractive therapeu-
tic candidate for prevention/treatment of T2DM.
Anorexic hormone obestatin is encoded by the preproghrelin gene that also encodes the orexigenic hormone 
ghrelin6. While high levels of obestatin are expressed in the oxyntic mucosa of the stomach, lower levels of obesta-
tin are also expressed in pancreatic islets1, 7, 8 and some other tissues2, 9–11. In the pancreas, obestatin is expressed 
in ε-cells of pancreatic islets, while ghrelin is expressed in α, β and ε-cells of the pancreatic islets1, 12–16. It is known 
that GHS-R is expressed in α, β and δ-cells of the pancreatic islets4, 17–21. Obestatin has been shown to antagonize 
ghrelin’s effects on appetite, food intake, gastric emptying6, 22, as well as growth hormone secretion23, 24. Obestatin 
is reduced in obese humans8. It has been reported that obestatin is positively correlated with insulin sensitivity25, 
and obestatin protects against diet-induced insulin resistance2. More interestingly, it has been shown that obesta-
tin increases β-cell proliferation and survival, and reduces inflammation-induced β-cell apoptosis1. Furthermore, 
obestatin has been shown to protect against streptozotocin (STZ)-induced β-cell failure in rats26.
We and others have reported that ghrelin inhibits insulin secretion4, 27–31, but the effect of obestatin on insulin 
secretion is not clear. While some studies showed that obestatin increases insulin secretion in human islets and 
diet-induced obese mouse islets1, others showed that obestatin inhibits insulin secretion7, 32 or has no effect on 
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insulin secretion33–35. To date, GHS-R is the only identified physiologically relevant receptor for ghrelin; ghrelin 
is the only ligand that is confirmed to bind to and function through GHS-R. Since the discovery of obestatin, 
the receptor of obestatin has been controversial. Initially, obestatin was suggested to be the endogenous ligand 
of orphan G-protein-coupled receptor 39 (GPR39)6, 36. However, subsequent studies failed to confirm specific 
binding of obestatin to GPR3937–40. Recently, some studies suggested that obestatin regulates survival and prolif-
eration of pancreatic β-cells via glucagon-like peptide-1 receptor (GLP-1R)1, 4, but others failed to detect the direct 
binding of obestatin to GLP-1R35. Interestingly, evidence does suggest that obestatin binds to a G-protein-coupled 
receptor (GPC-R)41–44, and GHS-R is a heterotrimeric GPC-R40. Further, it has been shown that obestatin inter-
acts with ghrelin binding sites, and pharmacological blocking of GHS-R abolishes obestatin’s protective effects 
on cell survival1.
Our study aims to investigate the effect of obestatin on GSIS and determine whether obestatin’s effect on 
GSIS is mediated through GHS-R. First, to study the effects of obestatin on insulin secretion, we utilized rat 
insulinoma INS-1 cells, as well as mouse pancreatic islets from ghrelin−/− mice lacking both ghrelin and obesta-
tin. Next, to investigate whether GHS-R mediates obestatin-induced GSIS, we used various model systems: a) 
in vitro system - INS-1 cells with either GHS-R pharmacologically blocked by GHS-R antagonists YIL781 & 
JMV2959, or Ghsr transiently suppressed by siRNA. b) in vivo system - Mice with Ghsr deleted globally (Ghsr−/−). 
c) ex vivo – Isolated islets from Ghsr−/− mice and β-cell-specific Ghsr knockout mice (MIP-Cre/ERT;Ghsrf/f). We 
demonstrated that obestatin augments insulin secretion in pancreatic β-cells under hyperglycemic condition, and 
obestatin-induced stimulatory effect on insulin is mediated through GHS-R. To our knowledge, this is the first set 
of comprehensive evidences showing that obestatin’s effect on GSIS is mediated through ghrelin receptor GHS-R.
Research Design and Methods
Animals. All experiments were approved by the Animal Care Research Committee of the Baylor College 
of Medicine. Animals were housed under controlled temperature and lighting (75 ± 1 °F; 12 h light-dark cycle) 
with free access to regular mouse chow and water. Our ghrelin−/−, Ghsr−/− mice on C57BL/6 J background were 
generated and characterized as we have previously described18, 45. Briefly, ghrelin−/− mice were backcrossed to 
C57BL/6 J background for 10 generations and Ghsr−/− mice were backcrossed for 15 generations. All mice used 
in the experiments were age-matched adult congenic males. WT and homozygous knockout mice (ghrelin−/−, 
Ghsr−/−) were housed and bred in a pathogen-free facility at Baylor College of Medicine, and all methods were 
performed in accordance with the relevant guidelines and regulations.
Ghsrf/f mice were originally obtained from Taconic Farms and were backcrossed as recently reported46, and 
then bred with MIP-Cre/ERT47 mice to generate MIP-Cre/ERT;Ghsrf/f. The Ghsrf/f and MIP-Cre/ERT;Ghsrf/f mice 
were gavaged five times with tamoxifen (4 mg/200 ul) in peanut oil on alternate days.
Reagents. Rat/Mouse obestatin peptide was from Phoenix Pharmaceuticals (Burlingame, CA). The GHS-R 
antagonists used were YIL781 (Tocris Bioscience, Bristol, UK) and JMV2959 (Calbiochem, San Diego, CA).
Cell Culture and siRNA transfection. INS-1 cells (832/13 cells) were a generous gift from Chris Newgard 
(Duke University)48. The cells were cultured in RPMI-1640 (Corning Incorporated, NY) containing 11.1 mM 
D-glucose supplemented with 10% inactivated fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 
10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate and 50 µM β-mercaptoethanol48.
For siRNA knockdown of Ghsr expression, INS-1 cells were plated in a 24-well plate at 0.5*10−6 cells/
well and cultured until confluent; they were then transfected with scramble/siGhsr and Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) as per the manufacturer’s instruction. Briefly, 2.5 μl of 40 μM scramble/siGhsr was 
added to 60 μl Opti-MEM media (Invitrogen, Carlsbad, CA) in an RNase-free tube. In a separate RNase-free 
tube, 2.5 μl Lipofectamine2000 (Invitrogen, Carlsbad, CA) was added to 60 μl Opti-MEM media, mixed 
and incubated for 5 min at room temperature. After 5 min, the scramble/siGhsr mix was combined with the 
Lipofectamine2000 mix to a total volume of 125 μl. The solution was mixed gently and incubated at room tem-
perature for 20 mins. During the incubation, the RPMI-1640 medium in the 24-well plate was replaced with 
125 ul low serum RPMI-1640 media containing 5% FBS and 1% INS-1 supplement without any antibiotic. After 
20 min, the scramble/siRNA/Lipofectamine2000 mix was added to the wells. The final siRNA concentration 
is 0.4 uM in a final volume of 250 ul/well. The plate was then incubated for 4 hours at 37 °C in a humidified 
incubator with 5% CO2. After 4 hours, 1 ml of RPMI-1640 was added to each well and plate was incubated at 
37 °C in the incubator. After overnight culture, the media was replaced with 1 ml of fresh RPMI-1640 media 
and incubated overnight. 48 hours after the start of transfection, the cells were harvested and used for insulin 
secretion or RNA/protein analysis. The siRNA sequences were designed with ABI software and synthesized by 
Sigma-Aldrich Scramble (Sense strand): 5′-CAACAACGAAGCGACAUAAUC-3′; Scramble (Antisense strand): 
5′-UUAUGUCGCUUCGUUGUUGUC-3′ or siGhsr (Sense strand) 5′-CCACAAACAGACAGUGAAGUU-3′; 
siGhsr (Antisense strand): 5′-CUUCACUGUCUGUUUGUGGUU-3′.
Insulin secretion experiments. INS-1 cells (passage numbers 24–40) were plated in a 24-well plate at a 
density of ~0.5 × 10−6 cells/well and were grown to near confluence. For islet culture experiments, islets were 
collected using the collagenase method (Collagenase P, Roche, Basel, Switzerland)49 and were cultured over-
night. Briefly, 3 ml of 1 mg/ml collagenase P was injected into the opening of the pancreatic duct using a 27 G 
needle. Pancreas was then removed and placed in 50 ml tube containing 2 ml of the collagenase solution. The 
tube was later placed in 37 °C water bath for 12–13 minutes with 100–120 shakings/min until the tissues were 
homogenously digested. 20 ml cold HBSS was subsequently added to stop the digestion and the tubes were cen-
trifuged at 290 g for 30 seconds at 4 °C. The islets were then centrifuged using a Ficoll gradient Histopaque-1077 
(Sigma-Aldrich, Kawasaki, Japan) per manufacturer’s instruction. Lastly the islets were handpicked and 
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incubated overnight in RPMI-1640 medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/
ml streptomycin, 10 mM Hepes, 2 mM L-glutamine, 1 mM Sodium-pyruvate, 0.05 mM 2-mercaptoethanol and 
5.5 mM glucose. The next day, the medium was replaced with Hanks’ Balanced Salt solution (HBSS) pH 7.2, 
consisting of 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM HEPES, 2.5 mM CaCl2, 
25.5 mM NaHCO3 0.2% bovine serum albumin and 3.3 mM glucose for 2 hr48. For insulin secretion experiments, 
cells were incubated in 0.5 ml of the secretion media mentioned above, but containing the indicated glucose 
concentrations with or without obestatin. For GHS-R antagonist experiments, cells were incubated with 5 µM of 
antagonist in the HBSS buffer, containing 3.3 mM glucose for 1 hour prior to obestatin treatment; the buffer was 
then replaced with 500 µl of fresh HBSS containing high glucose (22.2 mM) with the indicated concentrations of 
obestatin and/or antagonist.
Real-time RT-PCR. Total RNA from islets was isolated using Arcturus PicoPure RNA isolation kit (ABI) 
following the manufacturer’s instructions. cDNA was synthesized from 250–500 ng RNA using the SuperScript 
III First-Strand Synthesis System (Invitrogen, Carlsbad, CA). Real-time RT-PCR was performed on Bio-Rad real 
time PCR cycler (Bio-Rad Lab., Hercules, CA) using SYBR Green PCR Master Mix according to the protocol pro-
vided by the manufacturer. Relative gene expression levels were normalized by 18S rRNA or β-Actin. The primers 
specific for mouse GHS-R-1a were as follows: forward primer 5′-GGACCAGAACCACAAACAGACA-3′, reverse 
primer 5′-CAGCAGAGGATGAAAGCAACA-3′50, and can distinguish the functional receptor GHS-R 1a from 
truncated receptor GHS-R 1b.
Glucose tolerance testing and Re-feeding experiments. To assess the effect of obestatin on insu-
lin secretion in vivo, mice were fasted overnight (18 hrs) and then injected intraperitoneally (i.p.) with either 
0.5 µmol/kg (1.26 mg/kg) obestatin35 or saline, and then oral glucose tolerance test (OGTT) was performed 
immediately by gavaging 2 g/kg glucose. Blood samples for glucose and insulin measurements were obtained at 0, 
15, and 60 minutes after the administration of obestatin and glucose. For re-feeding experiments, the mice were 
fasted overnight (18 hrs) and were i.p. injected with either 0.5 µmol/kg obestatin or saline, and then provided with 
chow. Blood glucose and insulin samples were obtained at 0, 15, 30, 60 min after refeeding. Glucose was measured 
using OneTouch Ultra2 glucometer (LifeScan Inc., Milpitas, CA). Insulin in EDTA-treated plasma was measured 
using Mouse Insulin ELISA kit (Mercodia, Uppsala, Sweden) per the manufacturer’s instructions.
Statistical analysis. Graph-Pad Prism version 6.0 software was used. Two-way ANOVA with repeated 
measures or one-way ANOVA was used for statistical analysis. Data are represented as mean ± SEM, and P < 0.05 
was considered statistically significant.
Results
Obestatin enhances glucose-stimulated insulin secretion (GSIS). To determine the effect of obesta-
tin on insulin secretion, we utilized the rat insulinoma INS-1 cells and the pancreatic islets isolated from our pre-
proghrelin knockout mice (ghrelin−/−) where both ghrelin and obestatin coding sequences were deleted45. When 
INS-1 cells were treated with different concentrations of obestatin, the levels of insulin secretion were similar to 
controls at 3.3 mM low glucose condition. However, obestatin treatment significantly increased insulin secretion 
compared to controls at 22.2 mM glucose hyperglycemic condition (Fig. 1A). To exclude the endogenous effects 
of obestatin and ghrelin, we studied obestatin-induced GSIS in pancreatic islets from ghrelin−/− mice. Islets were 
treated with obestatin at 22.2 mM glucose condition for 1 hour. Consistent with our observation in INS-1 cells, 
obestatin-treated islets showed significantly higher insulin secretion (Fig. 1B). Our results collectively show that 
exogenous obestatin treatment augments glucose-stimulated insulin secretion in β-cells and isolated pancreatic 
islets.
Figure 1. Obestatin increases glucose-stimulated insulin secretion (GSIS). β-cells or pancreatic islets were 
treated with different doses of obestatin in presence of 3.3 or 22.2 mM glucose for 1 hour. Insulin measured was 
normalized to total protein content of cells or islets. (A) INS-1 cells. (B) Pancreatic islets isolated from ghrelin−/− 
mice, and tested under glucose concentration of 22.2 mM. #P < 0.05 obestatin treatment vs saline treatment, per 
glucose concentration, n = 3–5.
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The effect of obestatin on GSIS is mediated by GHS-R in β-cells. The identity of the receptor for 
obestatin has been elusive. In order to investigate whether the effect of obestatin on insulin secretion is mediated 
by GHS-R in β−cells, we pharmacologically blocked GHS-R by using GHS-R antagonists YIL781 and JMV2959 
in INS-1 cells. The GHS-R antagonists alone showed no effect on insulin secretion. Treatment of 100 nM obesta-
tin significantly increased insulin secretion from treated cells as compared to controls. However, when cells were 
treated with a combination of obestatin and GHS-R antagonists, the stimulatory effect of obestatin on insulin 
secretion was eliminated (Fig. 2A).
Next, we suppressed GHS-R expression in INS-1 cells by transiently knocking down Ghsr expression with 
siGHS-R. Ghsr expression in siGhsr-transfected cells was reduced by 60–70% as compared to scrambled siRNA 
treated cells after 48 hours (Fig. 2B). The scrambled and siGhsr-transfected cells were treated with 1 nM, 10 nM 
and 100 nM obestatin in the presence of 22.2 mM glucose for 1 hour. Obestatin-induced GSIS was observed with 
the scrambled siRNA-treated cells under different concentrations of obestatin, but not in the siGhsr-transfected 
cells (Fig. 2C). These results indicate that absence of GHS-R attenuates obestatin-induced GSIS in β-cells.
Obestatin-induced insulin secretion is abolished in GHS-R null mice. Our results in INS-1 
cells show that absence of GHS-R attenuates obestatin-induced GSIS. To determine the implications of 
Figure 2. The effect of obestatin on GSIS is mediated by GHS-R in β-cells. (A) INS-1 cells were treated with 
5 µM GHS-R antagonists YIL781 or JMV2959 for 1 hour, and insulin secretion was measured at 22.2 mM 
glucose with or without 100 nM obestatin. #P < 0.05, treatment vs control; *P < 0.05 obestatin vs obestatin with 
GHS-R antagonist, n = 8–14. (B) GHS-R was transiently knocked down in INS-1 cells and gene expression was 
measured after 48 hours. (C) Scrambled or siGhsr transfected INS-1 cells were treated with different doses of 
obestatin at 22.2 mM glucose for 60 minutes. Insulin was normalized to total protein content of cells. #P < 0.05 
obestatin treatment vs control for each genotype, *P < 0.05 scrambled vs siGhsr, n = 5.
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obestatin on insulin secretion in vivo, we further investigated obestatin-induced GSIS in Ghsr−/− mice. We treated 
overnight-fasted wild-type (WT) and Ghsr−/− mice with either obestatin (0.5 µmol/kg i.p) or saline, and then car-
ried out OGTT. At 15 minutes after glucose administration: 1) obestatin-treated WT mice displayed glucose levels 
comparable to that of saline-treated WT mice, respectively (Fig. 3A). 2) Insulin in obestatin-treated WT mice 
increased from 0.37 + 0.2 ng/ml to 4.95 + 0.32 ng/ml, while insulin in saline-injected group only increased from 
0.71 + 0.34 ng/ml to 2.36 + 0.38 ng/ml (Fig. 3B). Thus, obestatin-treated WT mice showed significantly higher 
GSIS compared to those of the saline-injected group. In contrast, glucose and insulin levels were not different 
between obestatin-injected Ghsr−/− mice and the saline-injected Ghsr−/− mice after 15 minutes of glucose and 
obestatin administration (Fig. 3C,D).
To assess the effect of obestatin on insulin secretion under physiological condition, we also investigated 
the effect of obestatin on insulin secretion in response to regular chow feeding. WT and Ghsr−/− mice were 
fasted overnight, then i.p. injected with 0.5 µmol/kg obestatin and fed with chow. After 30 minutes of feeding, 
glucose levels were comparable in both WT and Ghsr−/− mice (Fig. 3E,G). Similar to OGTT, insulin levels in 
obestatin-treated WT mice were significantly higher when compared to the saline-treated WT mice, with insulin 
levels at 2.24 + 0.28 ng/ml with obestatin and 1.33 + 0.05 ng/ml with saline at 30 minute time point (Fig. 3F). 
However, in Ghsr−/− mice, insulin levels were similar between the obestatin- and saline-treated groups at both 30 
and 60 minute time points (Fig. 3H).
These data indicate that obestatin increases insulin secretion in WT mice, but this effect is absent in 
Ghsr−/− mice under both oral glucose challenge and chow feeding. Also note-worthy is that the response of 
obestatin-induced insulin is rapid, and this effect is diminished within an hour. These studies suggest that obesta-
tin is an import regulator of insulin secretion in vivo and GHS-R is required for obestatin’s action on insulin 
secretion.
Obestatin’s effect on insulin secretion is mediated directly by GHS-R in pancreatic β-cells. We 
next validated the necessity of GHS-R for obestatin-induced GSIS in pancreatic islets. We isolated pancreatic 
islets from WT and Ghsr−/− mice and treated them with obestatin at 22.2 mM glucose. Similar to our findings 
in the β-cells, obestatin treatment at both obestatin doses increased the insulin secretion of WT islets, but did 
not affect insulin secretion of Ghsr−/− islets (Fig. 4A). The data further demonstrated that GHS-R mediates 
obestatin-induced GSIS.
Since GHS-R is expressed in α, β and δ-cells of pancreatic islets, we further investigated whether GHS-R 
in pancreatic β-cells alone determines obestatin’s effect on GSIS. To this end, we generated β-cell-specific Ghsr 
knockout mice by breeding MIP-Cre/ERT47 with our Ghsrf/f mice51. The MIP-Cre/ERT line is widely accepted as 
the β-cell-specific Cre line47. To validate the mouse model, we measured Ghsr expression in brain and peripheral 
tissues. Indeed, the reduced Ghsr expression was detected only in islets (around 30–34%), but not in other tissues 
Figure 3. Obestatin-induced insulin secretion is abolished in GHS-R null mice. Overnight-fasted WT and 
Ghsr−/− mice were i.p. injected with saline or 0.5 µmol/kg obestatin, and 2 g/kg glucose was gavaged. Blood 
glucose in WT (A) & Ghsr−/− (C) and plasma insulin in WT (B) & Ghsr−/− (D) was measured at 0, 15 and 
60 min after injection. #P < 0.05 saline/obestatin treatment at 15 min or 60 min vs saline/obestatin treatment at 
0 min, *P < 0.05 saline vs obestatin for each time point, n = 3–5. Overnight-fasted WT and Ghsr−/− mice were 
fed Ad. Lib. chow diet after saline/obestatin injections. Blood glucose in WT (E) & Ghsr−/− (G) and plasma 
insulin in WT (F) and Ghsr−/− (H) was measured at 0, 30 and 60 min after injection. #P < 0.05 saline/obestatin 
treatment at 30 min or 60 min vs saline/obestatin treatment at 0 min, *P < 0.05 saline vs obestatin for same time 
point, n = 6–8.
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tested (Data not shown). The reduction of Ghsr expression in pancreatic islets is likely due to Ghsr deletion in the 
β-cells, and the remaining GHS-R expression is likely due to the intact GHS-R expression in α and δ-cells of the 
islets. We isolated islets from tamoxifen-induced Ghsrf/f and MIP-Cre/ERT;Ghsrf/f mice, and treated them with 
obestatin for 1 hour at high glucose condition. Treatment of Ghsrf/f control islets with 100 nM obestatin signif-
icantly increased insulin secretion compared to controls, whereas obestatin treatment of islets from MIP-Cre/
ERT;Ghsrf/f mice exhibited no increase of insulin (Fig. 4B). These results indicate that obestatin has direct effect 
on pancreatic β-cells, and that GHS-R expression in β-cells is required for obestatin-induced GSIS (Fig. 4C).
Figure 4. Obestatin-induced insulin secretion is mediated directly by GHS-R expression in pancreatic β-cells. 
(A) Pancreatic islets from Ghsr−/− mice were treated with different doses of obestatin at 22.2 mM glucose 
concentration for 1 hour. Insulin was normalized to total protein content of islets. #P < 0.05 obestatin treatment 
vs saline control for each genotype, *P < 0.05 WT vs Ghsr−/− islets, n = 7–8. (B) Pancreatic islets from Ghsrf/f 
and MIP-Cre/ERT;Ghsrf/f mice were treated with 100 nM Obestatin at 22.2 mM glucose condition for 1 hour. 
Insulin was normalized to total protein content of islets. #P < 0.05 obestatin treatment vs control for each 
genotype, *P < 0.05 Ghsrf/f vs MIP-Cre/ERT;Ghsrf/f islets for each treatment group, n = 6–8. (C) Schematic of 
obestatin augments glucose-stimulated insulin secretion via GHS-R in β-cells.
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Discussion
In the current study, we used a comprehensive set of in vitro, ex vivo, and in vivo systems to investigate the effect 
of obestatin on GSIS, and whether GHS-R mediates the effect of obestatin on insulin secretion. We have found 
that: 1) Obestatin augments GSIS in INS-1 β-cells and pancreatic islets; 2) Obestatin-induced GSIS is abolished 
by GHS-R blockade/suppression in β-cells; 3) Obestatin increases insulin secretion in WT mice, but this effect is 
abolished in GHS-R knockout mice; 4) Obestatin-induced GSIS is absent in pancreatic islets isolated from global 
and β-cell-specific GHS-R knockout mice. Taken together, our data unambiguously demonstrate that obestatin 
augments insulin secretion under hyperglycemic state, and the stimulatory effect of obestatin on insulin is medi-
ated by ghrelin receptor GHS-R in pancreatic β-cells.
The effect of obestatin on insulin secretion is controversial. Qader et al. showed that obestatin inhibits insulin 
secretion in rat and mouse islets at 8.3 mM and 12 mM glucose concentrations, respectively32. Ren et al. showed 
that obestatin inhibits insulin secretion of pancreatic islets at high glucose concentration7. Egido et al. reported a 
dual, dose-dependent effect of obestatin on GSIS in perfused rat pancreas at 9 mM glucose: obestatin stimulated 
insulin secretion at low concentrations of obestatin (3.14 nM and 1 nM), but inhibited insulin secretion at a higher 
concentration of obestatin (10 nM)3. Several other studies have suggested that obestatin has no effect on insulin 
secretion7, 33–35.
Islets from the ghrelin−/− mice used in our study lack the coding sequences of both ghrelin and obestatin45, 
thus obestatin’s effect observed in ghrelin−/− islets is not affected by endogenous ghrelin or obestatin. The 
stimulatory effect of obestatin on GSIS is intact in ghrelin−/− mice, indicating that obestatin has direct effect 
on insulin secretion. In our study, injection of WT mice with 0.5 µmol/kg obestatin, and treatments of β-cells 
with 0.1–100 nM obestatin and pancreatic islets with 1–100 nM obestatin, all increased insulin secretion. Similar 
to our observations, Granata et al. reported that 100 nM obestatin increases insulin secretion in human islets1. 
Interestingly they found that obestatin has stimulatory effect on insulin at both high and low glucose concen-
trations in human islets1, but we only detected the effect under high glucose concentration in mouse islets. The 
discrepancy between high and low glucose concentrations in studies by us and Granata et al. could be due to dif-
ference in species of models studied. Granata et al. showed that the stimulatory effect of obestatin on GSIS persists 
under high fat diet condition2, and obestatin increases insulin in STZ-induced diabetic rats26. Recently Granata et 
al. also showed that obestatin enhances the generation of functional β cells in islet-like cell clusters derived from 
mouse pancreatic precursor cells, and obestatin increases insulin gene expression and C-peptide secretion from 
these clusters under glucose-stimulated condition52. These findings are well in line with our observations. The 
dosages of obestatin used in our study are higher than the usual physiological levels of the peptide in the blood, 
which range from 600 to 800 pg/ml33. However, the concentration of obestatin at the level of the islet is estimated 
to be much higher than its concentration in circulation, as obestatin is locally secreted from ε-cells in pancreatic 
islets12. It has been shown that only 70% of the circulating ghrelin originates from the stomach53, whereas the rest 
is derived from other tissues such as pancreas. The discrepancy between the reports from others and our data 
could be attributed to: a) species of origin of islets, b) different glycemic conditions and/or obestatin dose, c) the 
purity and potency of the peptide used in the studies, and/or d) duration of the obestatin treatment.
Similar to the debatable nature of obestatin’s effect on insulin secretion, the receptor mediating the actions 
of obestatin is even more elusive. Despite the detection of obestatin binding sites in various tissues such as pan-
creas and white adipose tissues1, 41, 54, obestatin is still considered an orphan ligand because its cognate receptor 
is uncertain. Originally, Zhang et al. suggested that obestatin’s actions may be mediated by GPR39 receptor, and 
demonstrated binding of obestatin to CHO cells expressing GPR39 receptor6, 36. Subsequent studies were not 
able to confirm the finding of Zhang et al. and failed to detect the activation of GPR39 with obestatin treat-
ment38–40. Later, GLP-1R was suggested to mediate the functions of obestatin, promoting β-cell survival and pro-
liferation1. However, experiments using GLP-1R overexpressing β-cells could not confirm the specific binding35. 
Interestingly, Granata et al. observed that besides GLP-1R, obestatin could also interact with acylated ghrelin 
binding sites, and obestatin-induced β-cell survival effect was ablated in the presence of GHS-R antagonist 
[D-Lys3]- GHRP61. GHS-R is a GPCR40, and several studies have suggested that obestatin likely binds and acti-
vates a GPCR41–44. It is possible that obestatin possesses low-affinity binding for GHS-R. We demonstrated that 
obestatin-induced GSIS in INS-1 β-cells is dependent on GHS-R expression; obestatin-induced GSIS is abolished 
in Ghsr−/− mice, and islets isolated from Ghsr−/− and β-cell-specific Ghsr knockout mice. These results definitively 
demonstrate that the stimulatory effect of obestatin on insulin secretion is mediated by GHS-R in pancreatic 
β-cells.
GHS-R is the only recognized biologically relevant receptor of ghrelin55 and is expressed in the brain and 
peripheral tissues including intestine, endocrine pancreas, and adipose tissues56. We have shown that GHS-R 
mediates ghrelin’s effects on food intake and growth hormone secretion18. Dezaki et al. has reported that 
ghrelin-induced inhibition of insulin secretion in β-cells is mediated through GHS-R57. Obestatin and ghrelin, 
both products of the preproghrelin gene, have opposing effects on insulin secretion as demonstrated by us and 
others. GSIS can be potentiated or suppressed by hormones and neural substances. Extensive research has estab-
lished ghrelin’s role in the regulation of insulin release and glycemic control. Ghrelin inhibits glucose-induced 
insulin release in vivo, and in perfused pancreas and isolated islets57–59. Our data indicate that obestatin has an 
insulin-stimulatory effect under hyperglycemic condition, which is opposite from the insulin-inhibitory effect 
of ghrelin. Several reports show that the ratio of obestatin/ghrelin is different in anorexia nervosa and obesity60, 
which suggests that the obestatin/ghrelin ratio may serve as a biomarker for different nutritional states. We have 
reported that fasting reduces plasma obestatin, but increases ghrelin in mice61. The stimulatory effect of obestatin 
and the inhibitory effect of ghrelin on insulin secretion are in line with their anorexic and orexigenic properties.
It is intriguing that both ghrelin and obestatin signal through GHS-R, yet have opposite effects on insulin secre-
tion. GHS-R activation is most commonly associated with coupling of GHS-R to G protein subunit Gαq/1155, 62. 
Interestingly, it has been reported that GHS-R couples with Gαi/o in the pancreatic islets to mediate ghrelin’s 
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inhibitory effect on GSIS63. Additionally, GHS-R has been shown to form heterodimers with other GPCRs, 
such as dopamine receptors DRD1, DRD264, 65, MC3R66 and 5-HT2C67 to transmit different functions. Park et 
al. showed that ghrelin inhibits insulin secretion in β cells via GHS-R1a heterodimerization with Somatostatin 
receptor-5 (SST5), where GHS-R1a couples to Gαi/o instead of Gαq/1168. It has been reported that GHS-R1a 
dimerizes with D1 to switch GHS-R1a coupling from Gαq/11 to Gαs in NPY cells of arcuate nucleus69, 70. We thus 
speculate that obestatin-induced GSIS in β-cells is mediated by the coupling of GHS-R1a to different G protein 
subunits: a) Gαq/11, to potentiate cytosolic Ca2+ levels subsequently increasing insulin secretion; b) Gαs, through 
heterodimerization of GHS-R with other GPCR, such as GLP-1R71, 72. While we have demonstrated that GHS-R is 
required for obestatin’s insulinotropic effect, we did not perform ligand binding assay or test response of obestatin 
in a heterologous GHS-R expression system. Thus we cannot definitively conclude that obestatin directly binds to 
GHS-R. Further studies are needed to test the direct binding of obestatin to GHS-R and/or obestatin-induced het-
erodimerization of GHS-R with other receptors. In depth understanding of the downstream signaling pathways 
mediating the opposing effects of ghrelin and obestatin in β-cells would be of interest as well.
It has been shown that obestatin plays important roles in the survival and function of pancreatic β-cells. 
Obestatin treatment improves the survival of β-cells and human islets by reducing apoptosis1. Obestatin enhances 
insulin sensing of pancreatic islets and streptozotocin-induced β-cells2, 32. Insulin receptor substrate 2 (IRS-2) 
was reported to reduce the incidence of diabetes in IRS-2-overexpressing non-obese diabetic mice73. It has been 
suggested that obestatin improves insulin sensitivity by increasing expression and phosphorylation of IRS-21. Our 
comprehensive in vitro, ex vivo and in vivo dataset collectively demonstrate that obestatin is also a potent insulin 
secretagogue, and the stimulatory effect of obestatin on insulin secretion is mediated by ghrelin receptor GHS-R 
in β-cells. Our finding of obestatin’s stimulatory effect on insulin combined with the other beneficial effects of 
obestatin on β-cells, makes obestatin an extremely attractive multifunctional therapeutic candidate for Type 2 
diabetes.
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